The Essential Data Layer for AI-Driven Medicine
RefinedScience systematically de-risks oncology and immunology drug assets by integrating high-fidelity clinical data with single-cell human tissue biology and functional testing to drive actionable insights from target to trial.
The Problem
AI is rapidly identifying drug candidates, but it does not solve the industry’s biggest problem: late-stage clinical failures.
The root cause of drug program failure is biology, not technology.
Preclinical models built on cell lines don’t reflect the complexity of human tumors. Drugs that work in simplified systems routinely fail when they encounter real biology.
Proxies and averages hide disease heterogeneity; drugs advance without biology understood at the level that determines success or failure.
As a result, promising therapies are abandoned before the right biology or patient population is understood.
Billions are spent advancing drugs without understanding disease biology at the level that determines success or failure.
The RefinedScience Platform
What AI alone cannot provide. A platform designed to connect biological discovery with clinical reality.
Oncology Indications
Where we have depth.
Our indications are built disease by disease—each one combining clinical records, biobank tissue, and single-cell omics into a longitudinal, multi-modal resource.
Active
Acute Myeloid Leukemia (AML)
Deepest indication. Longitudinal clinical data on 300+ patients with linked tissue. Venetoclax/azacitidine-treated patients with CITE-seq. Available on Verily Exchange.
Active
Pancreatic Ductal Adenocarcinoma (PDAC)
Single-cell profiling and spatial transcriptomics in one of oncology’s hardest indications. Target discovery and combination identification focus.
Active
Rheumatoid Arthritis (RA)
Single-cell profiling of synovial tissue and matched blood samples from patients with new-onset rheumatoid arthritis. Supports immune profiling and biomarker discovery. Please label it Early Pipeline.
EARLY PIPELINE
Myelodysplastic Syndromes (MDS)
Single-cell omics and clinical data in MDS—high unmet need with strong biological overlap with AML.
EARLY PIPELINE
Esophageal Cancer
Single-cell and clinical data in esophageal cancer. Supports target discovery and patient stratification research.
EARLY PIPELINE
Diffuse Large B-Cell Lymphoma (DLBCL)
Single-cell transcriptomics and clinical data in DLBCL for resistance profiling and patient stratification.
Coming Soon
Glioblastoma (GBM)
Multi-modal data in GBM. Single-cell resolution to characterize tumor microenvironment and identify subpopulation-specific targets.
Coming Soon
Ovarian Cancer
Single-cell omics dataset including high-grade serous histology. Supports antibody-based target discovery and patient stratification.
The essential data layer for AI-driven medicine
Let’s build the evidence that moves your program forward.